GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Retained Earnings

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Retained Earnings : €-235.4 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Biocytogen Pharmaceuticals (Beijing) Co's retained earnings for the quarter that ended in Jun. 2024 was €-235.4 Mil.

Biocytogen Pharmaceuticals (Beijing) Co's quarterly retained earnings declined from Jun. 2023 (€-205.5 Mil) to Dec. 2023 (€-229.5 Mil) and declined from Dec. 2023 (€-229.5 Mil) to Jun. 2024 (€-235.4 Mil).

Biocytogen Pharmaceuticals (Beijing) Co's annual retained earnings declined from Dec. 2021 (€-111.5 Mil) to Dec. 2022 (€-190.1 Mil) and declined from Dec. 2022 (€-190.1 Mil) to Dec. 2023 (€-229.5 Mil).


Biocytogen Pharmaceuticals (Beijing) Co Retained Earnings Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Retained Earnings Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Retained Earnings
- -111.48 -190.14 -229.53

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Retained Earnings Get a 7-Day Free Trial - -190.14 -205.45 -229.53 -235.35

Biocytogen Pharmaceuticals (Beijing) Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Biocytogen Pharmaceuticals (Beijing) Co  (FRA:I54) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Biocytogen Pharmaceuticals (Beijing) Co Business Description

Traded in Other Exchanges
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines